Antisense oligonucleotide controlling expression amount of TDP-43 and use thereof
The present invention provides a suppression type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in any of SEQ ID NOs: 2-4, and a promotion type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in SEQ ID NO: 5.
1. An antisense oligonucleotide targeting TAR DNA-binding domain 43 (TDP-43) mRNA, comprising a nucleotide sequence complementary to a sequence consisting of at least 15 continuous nucleotides in the nucleotide sequence of any of SEQ ID NOs: 2-4, wherein the oligonucleotide comprises modification of one or more kinds of sugar-phosphoric acid backbone.
2. The antisense oligonucleotide according to claim 1 , wherein the oligonucleotide consists of 15-30 nucleotides.
3. The antisense oligonucleotide according to claim 1 , wherein the complementary nucleotide sequence is the nucleotide sequence of any of SEQ ID NOs: 45-63 (wherein thymine may be uracil).
4. The antisense oligonucleotide according to claim 1 , wherein the oligonucleotide comprises 2′-O,4′-C-ethylene-bridged nucleic acid and deoxyribonucleotide.
5. The antisense oligonucleotide according to claim 4 , wherein the oligonucleotide is of a gapmer type.
6. The antisense oligonucleotide according to claim 1 , wherein the oligonucleotide consists of the nucleotide sequence of any of SEQ ID NOs: 11, 22-29 and 35-44.
7. An antisense oligonucleotide targeting TAR DNA-binding domain 43 (TDP-43) mRNA, comprising a nucleotide sequence complementary to a sequence consisting of at least 15 continuous nucleotides in the nucleotide sequence of SEQ ID NO: 5, wherein the oligonucleotide comprises modification of one or more kinds of sugar-phosphoric acid backbone.
8. The antisense oligonucleotide according to claim 7 , wherein the oligonucleotide consists of 15-30 nucleotides.
9. The antisense oligonucleotide according to claim 7 , wherein the oligonucleotide comprises 2′-O,4′-C-ethylene-bridged nucleic acid and 2′-O-methyl-modified nucleic acid.
10. The antisense oligonucleotide according to claim 7 , wherein the cytosine nucleotide and thymine nucleotide are 2′-O,4′-C-ethylene-bridged nucleic acids, and adenine nucleotide and guanine nucleotide are 2′-O-methyl-modified nucleic acids.
11. The antisense oligonucleotide according to claim 7 , wherein the oligonucleotide consists of the nucleotide sequence of SEQ ID NO: 84, 85 or 87.
12. The antisense oligonucleotide according to claim 1 , comprising a nucleotide sequence complementary to a sequence consisting of at least 19 continuous nucleotides in the nucleotide sequence of any of SEQ ID NOs: 2-4.
13. The antisense oligonucleotide according to claim 7 , comprising a nucleotide sequence complementary to a sequence consisting of at least 19 continuous nucleotides in the nucleotide sequence of SEQ ID NO: 5.
14. A method for regulating expression of TDP-43, comprising administering an effective amount of the antisense oligonucleotide according to claim 1 in vivo or in vitro.
15. A method for treating TDP-43 proteinopathy in a mammal, comprising administering an effective amount of the antisense oligonucleotide according to claim 1 to the mammal.
16. The method according to claim 15 , wherein the TDP-43 proteinopathy is amyotrophic lateral sclerosis or frontotemporal dementia.